BRAIN Biotech Overview

  • Year Founded
  • 1993

Year Founded

  • Status
  • Public

  • Employees
  • 268

Employees

  • Stock Symbol
  • BNN

Stock Symbol

  • Investments
  • 14

  • Share Price
  • $2.83
  • (As of Friday Closing)

BRAIN Biotech General Information

Description

BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • Darmstädter Strasse 34-36
  • 64673 Zwingenberg
  • Germany
+49 06251
Primary Industry
Biotechnology
Stock Exchange
ETR
Vertical(s)
Corporate Office
  • Darmstädter Strasse 34-36
  • 64673 Zwingenberg
  • Germany
+49 06251

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BRAIN Biotech Stock Performance

As of 13-Nov-2026, BRAIN Biotech’s stock price is $2.83. Its current market cap is $61.8M with 21.8M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.83 $2.85 $2.51 - $4.48 $61.8M 21.8M 5.76K -$0.75

BRAIN Biotech Financials Summary

As of 30-Jun-2026, BRAIN Biotech has a trailing 12-month revenue of $53.6M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 30-Sep-2025 FY 2024 30-Sep-2024 FY 2023 30-Sep-2023
EV 73,707 55,871 53,080 99,185
Revenue 53,612 55,191 59,383 59,042
EBITDA (6,158) (5,398) (4,638) (2,108)
Net Income (16,301) (12,957) (12,067) (8,834)
Total Assets 67,816 77,819 99,110 75,087
Total Debt 31,617 10,011 14,663 4,932
Public Fundamental Data provided by Morningstar, Inc. disclaimer

BRAIN Biotech Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore BRAIN Biotech‘s full profile, request access.

Request a free trial

BRAIN Biotech Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, a
Biotechnology
Zwingenberg, Germany
268 As of 2026

Leipzig, Germany
 

Bedford, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

BRAIN Biotech Competitors (3)

One of BRAIN Biotech’s 3 competitors is c-LEcta, a Formerly PE-Backed company based in Leipzig, Germany.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
c-LEcta Formerly PE-Backed Leipzig, Germany
Conagen Corporate Backed or Acquired Bedford, MA
Lonza Group Corporation Basel, Switzerland
You’re viewing 3 of 3 competitors. Get the full list »

BRAIN Biotech Patents

BRAIN Biotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4732825-A1 An antioxidant composition comprising a cinnamic acid derivative Pending 25-Oct-2024
WO-2026087745-A1 An antioxidant composition comprising a cinnamic acid derivative Pending 25-Oct-2024
WO-2025247966-A1 Process for protein production in methylotrophic yeast host cell. Pending 29-May-2024
EP-4461740-A1 A modified yeast strain for low alcohol fermentation Pending 12-May-2023
EP-4461741-A1 A modified yeast strain for low alcohol fermentation Pending 12-May-2023 C07K14/395
To view BRAIN Biotech’s complete patent history, request access »

BRAIN Biotech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BRAIN Biotech Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore BRAIN Biotech‘s full profile, request access.

Request a free trial

BRAIN Biotech Investments & Acquisitions (14)

BRAIN Biotech’s most recent deal was a Secondary Transaction - Private with Breatec. The deal was made on 20-May-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Breatec 20-May-2025 Secondary Transaction - Private Specialty Chemicals
Biocatalysts 24-Nov-2023 Secondary Transaction - Private Specialty Chemicals
SolasCure 27-Mar-2023 Later Stage VC Drug Discovery
Breatec 01-Feb-2022 Merger/Acquisition Specialty Chemicals
Biocatalysts 12-May-2021 Secondary Transaction - Private Specialty Chemicals
You’re viewing 5 of 14 investments and acquisitions. Get the full list »

BRAIN Biotech ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Chemicals

Industry

Rank

Percentile

Specialty Chemicals

Subindustry

Rank

Percentile

To view BRAIN Biotech’s complete esg history, request access »

BRAIN Biotech Exits (1)

BRAIN Biotech’s most recent exit was on 01-Jan-2011 from MONTEIL Cosmetics International. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
MONTEIL Cosmetics International 01-Jan-2011 Completed
To view BRAIN Biotech’s complete exits history, request access »

BRAIN Biotech Affiliates

Subsidiaries (3)

Name Industry Location Year Founded
WeissBioTech Ascheberg, Estonia 2002
AnalytiCon Discovery Potsdam, Germany 2000
Biocatalysts Cardiff, United Kingdom 1983

BRAIN Biotech FAQs

  • When was BRAIN Biotech founded?

    BRAIN Biotech was founded in 1993.

  • Where is BRAIN Biotech headquartered?

    BRAIN Biotech is headquartered in Zwingenberg, Germany.

  • What is the size of BRAIN Biotech?

    BRAIN Biotech has 268 total employees.

  • What industry is BRAIN Biotech in?

    BRAIN Biotech’s primary industry is Biotechnology.

  • Is BRAIN Biotech a private or public company?

    BRAIN Biotech is a Public company.

  • What is BRAIN Biotech’s stock symbol?

    The ticker symbol for BRAIN Biotech is BNN.

  • What is the current stock price of BRAIN Biotech?

    As of 13-Nov-2026 the stock price of BRAIN Biotech is $2.83.

  • What is the current market cap of BRAIN Biotech?

    The current market capitalization of BRAIN Biotech is $61.8M.

  • What is BRAIN Biotech’s current revenue?

    The trailing twelve month revenue for BRAIN Biotech is $53.6M.

  • Who are BRAIN Biotech’s competitors?

    c-LEcta, Conagen, and Lonza Group are competitors of BRAIN Biotech.

  • What is BRAIN Biotech’s annual earnings per share (EPS)?

    BRAIN Biotech’s EPS for 12 months was -$0.75.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process